Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.

Science advances·2026
Same author

Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The Use of Deep Learning in RNA Therapeutic Development.

ACS nano·2026
Same author

Wireless battery-free oxygenation devices enable extended immunosuppression-free islet transplantation in minimally invasive sites.

Device·2026
Same author

The long noncoding RNA <i>lnc-FAM164A1</i>-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approach.

Frontiers in immunology·2026
Same author

Intramolecular bonding as a design strategy for robust intermolecular binding of oligomers.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: May 17, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Rationally designed tumor-penetrating nanocomplexes.

Emmanouil D Karagiannis1, Christopher A Alabi, Daniel G Anderson

  • 1David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

ACS Nano
|October 24, 2012
PubMed
Summary

Researchers developed novel peptide-based nanocomplexes for targeted delivery of small interfering RNA (siRNA) therapeutics. These advanced formulations effectively silenced a key oncogene in ovarian cancer models, significantly reducing tumor burden and improving survival rates.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: May 17, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • Small interfering RNA (siRNA) therapeutics offer vast medical potential but necessitate safe and efficient delivery systems.
  • Ideal siRNA delivery vehicles must protect cargo, target specific cells, facilitate cellular entry, and enable intracellular release.

Purpose of the Study:

  • To design and evaluate novel peptide-based nanocomplexes for targeted siRNA delivery to tumor cells.
  • To investigate the structure-activity relationships of these nanocomplexes using computational modeling.

Main Methods:

  • Systematic assembly of myristoylated tandem peptides with tumor-targeting and cell-penetrating modules.
  • Formulation of peptides and siRNAs into nanocomplexes for cell-specific delivery.
  • Computational analysis to correlate nanocomplex structure with cell-type-specific activity.
  • In vivo testing in an ovarian cancer model using siRNA targeting the ID4 oncogene.

Main Results:

  • Peptide-nanocomplexes demonstrated cell-specific delivery and gene silencing in various tumor cell lines.
  • Computational modeling identified ligand valence and nanocomplex charge as critical for activity.
  • In vivo studies showed significant tumor burden reduction and an 80% increase in mouse survival.
  • The developed system effectively delivered siRNA against the ID4 oncogene.

Conclusions:

  • A systematic, rational design approach combined with computational modeling can optimize siRNA delivery vehicles.
  • Peptide-based nanocomplexes represent a promising platform for potent and targeted siRNA therapeutics.
  • This strategy holds potential for improving cancer treatment outcomes through advanced gene silencing strategies.